- Previous Close
0.9300 - Open
0.7800 - Bid 0.6700 x --
- Ask 0.6900 x --
- Day's Range
0.6200 - 0.7800 - 52 Week Range
0.6200 - 7.4500 - Volume
316,962 - Avg. Volume
58,488 - Market Cap (intraday)
29.175M - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2800 - Earnings Date Mar 17, 2025 - Mar 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
briacell.com--
Full Time Employees
July 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: BCT.TO
View More
Performance Overview: BCT.TO
Trailing total returns as of 2025-01-06, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCT.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCT.TO
View MoreValuation Measures
Market Cap
41.11M
Enterprise Value
32.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-126.11%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.79M
Diluted EPS (ttm)
-1.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
862.09k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.83M